2171015-78-2
Chemical Structure
RSC-1255
- CAS No.: 2171015-78-2
- Formula:C27H25ClF4N4O3
- Molecular Weight:564.96
InChIKey: JDSOPSVHZBKHQC-UHFFFAOYSA-N
SMILES: O=C(C1(C)N(C2=CC=C(C=C2F)F)N=C(C1C3=CC=C(Cl)O3)C4=C(F)C=C(F)C=C4)NCC5OCCN(C5)C
Biological Activity: RSC-1255 is a potent and selective Vacuolar H⁺-ATPase (V-ATPase) inhibitor that directly binds the mammalian V-ATPase complex with a Kd = 23 nM. RSC-1255 exhibits preferential cytotoxicity toward KRAS-mutant cancer cells, especially KRASG13D and KRASG12V cells. RSC-1255 induces apoptosis and blocks lysosomal acidification, autophagy, and macropinocytosis in cancer cells. RSC-1255 can be used for the study of KRAS-driven lung and colon cancers[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RSC-1255 | 99.91% | RSC-1255 is a potent and selective Vacuolar H⁺-ATPase (V-ATPase) inhibitor that directly binds the mammalian V-ATPase complex with a Kd = 23 nM. RSC-1255 exhibits preferential cytotoxicity toward KRAS-mutant cancer cells, especially KRASG13D and KRASG12V cells. RSC-1255 induces apoptosis and blocks lysosomal acidification, autophagy, and macropinocytosis in cancer cells. RSC-1255 can be used for the study of KRAS-driven lung and colon cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
